Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
Tirzepatide (15mg weekly) Dual GLP-1/GIP receptor agonist. Delays gastric emptying, extends satiety, potentiates insulin secretion 20.9% at 72 weeks (SURMOUNT-1) GI side effects in 40–50% during titration; pancreatitis risk <1% F…
Survodutide Dual GLP-1/glucagon agonist 12.5–14.7% Nausea (40%), diarrhea (28%), elevated heart rate (15%) Fastest fat oxidation due to hepatic glucagon signaling. Best for patients who plateau on GLP-1 monotherapy Mazdutide GLP-…
GLP-1 Agonists (Semaglutide, Tirzepatide) Slows gastric emptying, extends satiety signaling, delays ghrelin rebound 15–22% body weight over 68–72 weeks Addresses age-related leptin resistance and compensatory hunger mechanisms Na…
Before selecting a peptide protocol, understand what each mechanism addresses and where it fits in the postmenopausal metabolic landscape. | Peptide/Class | Primary Mechanism | Target Population | Expected Weight Loss (12–24 week…
This table ranks peptides by fat loss efficacy in sedentary protocols based on clinical trial data and mechanism of action. Tirzepatide Dual GIP/GLP-1 agonist. Appetite suppression + delayed gastric emptying 20.9% at 72 weeks (SU…
Tirzepatide Dual GLP-1/GIP agonist. Enhances insulin secretion + peripheral glucose uptake 20.9% (SURMOUNT-1, 15mg weekly) HOMA-IR reduced 45% by week 20; fasting insulin down 38% Free androgen index reduced 28% by week 24 (indep…